| DC10126 |
E-64c
Featured
|
E-64c is a synthetic analog of E-64, a potent and irreversible cysteine protease inhibitor isolated from Aspergillus japonicus. |
|
| DC8485 |
E-64d(Aloxistatin)
Featured
|
E-64D is an inhibitor of cathepsins B and L; also thought to inhibit calpain,showed a potent activity for COVID-19(SARS-COV-2)with EC50: MERS-COV(1.275),SARS-COV(0.760) |
|
| DC10563 |
E-7046
Featured
|
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
|
| DC5065 |
Golvatinib (E7050)
Featured
|
E-7050 is hepatocyte growth factor receptors (HGFR). |
|
| DC8488 |
LENVATINIB MESYLATE
Featured
|
E7080 (Lenvatinib) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. |
|
| DC7116 |
E7080 (Lenvatinib)
Featured
|
E7080 (Lenvatinib; Vargatef) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. |
|
| DC22085 |
Tasurgratinib（E7090)
Featured
|
E7090 (E 7090) is a highly potent and selective orally bioavailable inhibitor targeting FGFR1, FGFR2, and FGFR3, with IC50 values of 0.71 nM, 0.50 nM, and 1.2 nM, respectively. It exhibits significantly weaker inhibition of FGFR4, with an IC50 of 120 nM. This distinct selectivity profile positions E7090 as a promising therapeutic candidate for diseases driven by aberrant FGFR1-3 signaling, offering a targeted approach to inhibit these receptors while minimizing off-target effects on FGFR4. Its oral availability further enhances its potential as a convenient and effective treatment option for patients with FGFR-dependent conditions. |
|
| DC10976 |
E-7386
Featured
|
E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively. |
|
| DC9983 |
E-7449
Featured
|
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors. |
|
| DC10784 |
E7820
Featured
|
E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells. |
|
| DC9665 |
EAI045
Featured
|
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. |
|
| DC9534 |
EBE-A22
Featured
|
EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.
|
|
| DC11477 |
EBI-2511
Featured
|
EBI-2511 is a highly potent and orally active EZH2 inhibitor for the treatment of Non-Hodgkin’s Lymphoma. |
.gif)
|
| DC9848 |
Ebselen
Featured
|
Ebselen is a selenium-based inhibitor of protein kinase C, NADPH, 5-lipoxygenase, cyclooxygenase (COX) and NADPH oxidase. |
|
| DC10277 |
EC330
Featured
|
EC330 is a leukemia inhibitory factor (LIF) inhibitor. |
|
| DC26057 |
Ecabet (sodium salt)
Featured
|
Ecabet is an antiulcerative and gastroprotective agent. |
|
| DC9912 |
Echinocystic acid
Featured
|
Echinocystic acid a pentacyclic triterpene isolated from the fruits of Gleditsia sinensis Lam, has potent antioxidant, anti-inflammatory and anti-tumor properties. |
|
| DC21002 |
Edelfosine
Featured
|
Edelfosine is a synthetic lysophospholipid analog that selectively inhibits PLC with IC50 of 9.6 uM in fibroblasts and adenocarcinoma cells. |
|
| DC11398 |
Edicotinib（JNJ-40346527）
Featured
|
Edicotinib（JNJ-40346527）is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. |
|
| DC10762 |
Edonerpic maleate
Featured
|
Edonerpic, also known as T-817, is a neuroprotectant. Edonerpic is a candidate therapeutic agent for Alzheimer's disease that inhibits oxidative stress and nitric oxide-induced neurotoxicity and acts as a neurotrophic factor. Edonerpic protects against MPTP-induced neurotoxicity by blocking lipid peroxidation in the SNc, and imply that this compound may be useful for treating neurodegenerative disorders related to oxidative stress, such as Parkinson's disease. |
|
| DC8305 |
Edoxaban
Featured
|
Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention |
|
| DC8793 |
Edoxaban tosylate monohydrate
Featured
|
Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention |
|
| DC7819 |
Efaproxiral sodium
Featured
|
Efaproxiral Sodium is a synthetic allosteric modifier of hemoglobin, used for brain metastases originating from breast cancer. |
|
| DC9772 |
Efinaconazole(KP-103)
Featured
|
Efinaconazole(KP-103) is a novel triazole antifungal drug currently under development as a topical treatment for onychomycosis. |
|
| DC9378 |
Efonidipine (hydrochloride monoethanolate)
Featured
|
Efonidipine(NZ-105) Hcl monoethanolate is a dual T-type and L-type calcium channel blocker (CCB).
|
|
| DC9755 |
eFT508(Tomivosertib)
Featured
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
|
| DC9270 |
Eg5 Inhibitor III（Dimethylenastron）
Featured
|
Eg5 Inhibitor III, Dimethylenastron is a cell-permeable quinazoline-thione compound that acts as a strong, specific, and reversible inhibitor of the microtubule-stimulated ATPase activity of the mitotic motor, Eg5. |
|
| DC11018 |
EGFR-IN-99
Featured
|
EGFR-IN-99 (compound 1a) is a potent EGFR and HER2 Exon 20 insertion mutant inhibitor. EGFR-IN-99 has excellent antiproliferative activity against DFCI127 cells, with an EC50 of 11.5 nM. EGFR-IN-99 can be used for the research of non-small cell lung cancer (NSCLC). |
|
| DC7728 |
EHop-016
Featured
|
EHop-016 is a novel inhibitor of Rac GTPase with IC50 of 1.1 μM for Rac1, equally potent inhibition for Rac3. |
|
| DC7627 |
EHT-1864
Featured
|
EHT 1864 is a potent Rac family GTPase inhibitor with Kd of 40 nM, 50 nM, 60 nM and 250 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. |
|
